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 Ezetimibe is an anti hyperlipidemic drug which has poor aqueous solubility (0.00846 gm/L) 
and low bioavailability (35%). The SLNs were prepared using high speed homogenization 
technique. Glyceryl monostearate (GMS) and Poloxamer 188 were employed as lipid 
carrier and surfactant respectively. A two factor, three level (3
2
) full factorial design 
was applied to study the effect of independent variables i.e. amount of GMS (X 1) and 
amount of Poloxamer 188 (X 2) on dependent variables i.e. Particle size (Y 1 ), % 
Entrapment efficiency (Y2) and % Cumulative drug release at 24hour (Y3). Particle size, 
Poly dispersity index (PDI), % Entrapment efficiency (%EE), zeta potential, drug content, 
in vitro drug release and particles morphology were evaluated for SLNs. Contour plots and 
response surface plots showed visual representation of relationship between the 
experimental responses (dependent variables) and the set of input (independent) variables. 
The optimized batch (B10) contained 500 mg of GMS and 750 mg of Poloxamer 188. 
Batch B10 exhibited particle size of 38.91±2.23 nm; Polydispersity index (PDI) of 
0.221±0.091; zeta potential of -0.623 mV; % EE of 78.1±0.916% and % CDR at 24 hour 
of102.61±0.927%. The drug release experiments exhibited an initial rapid release 
experiments exhibited an initial rapid release followed by sustained release extended up 
to 24 hour. Differential scanning calorimetry (DSC) studies hoed that there was no 
chemical interaction between drug and lipid. The developed formulation may be 
adsorbed via the lymphatic route thereby avoiding hepatic first pass metabolism. This 
may lead to improvement in bioavailability, reduction dose and dose related side effect, 
etc. 
Please cite this article in press as Pranav Shah et al. Formulation and Evaluation of Ezetimibe Loaded Solid Lipid 
Nanoparticles. Indo American Journal of Pharmaceutical Research.2017:7(08). 
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INTRODUCTION 
Ezetimibe is an antihyperlipidemic drug which is belongs to the cholesterol absorption inhibitor category. Ezetimibe 
indicated as adjunctive therapy to the diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein 
cholesterol (LDL-C), apolipoprotein B (Apo B), and non-high density lipoprotein cholesterol (non HDL-C) in patients with 
primary (heterozygous familial and non-familial) hyperlipidemia. Ezetimibe is classified as a class II drug based on the 
biopharmaceutical classification system, because of its low water solubility and high permeability. They often show low oral 
bioavailability because of their slow and limited drug release in the alkaline environment of intestine, application of the strategies 
that improve the dissolution and/or apparent solubility of this poorly water-soluble drug of particular importance to increase its 
oral bioavailability.
(1,2)
 
Hypercholesterolemia (Hyperlipidemia) is a condition characterized by very high levels of cholesterol in the blood. 
Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals. Too 
much cholesterol, however, increase a person's risk of developing heart disease. (3) People with hypercholesterolemia have a high 
risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the 
bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). 
Solid lipid nanoparticles (SLNs) are attractive submicron colloidal carriers (10-1000 nm) for hydrophilic as well as lipophilic 
drugs.
 
The drugs are entrapped in biocompatible lipid core and surfactant at the outer shell (Figure 1. Diagram of solid lipid 
nanoparticle). SLNs can be employed to improve the bioavailability and to obtain sustained at the outer shell. SLNs can be 
employed to improve the bioavailability and to obtain sustained release of the drug. They provide advantages like lack of acute 
and chronic toxicity of the carrier, good tolerability and biodegradability as well as scalability to large production.  In addition, 
the protected against chemical/enzymatic degradation.  Hence, SLNs are considered to be better alternative than polymeric 
nanoparticles, [55] liposomes, microemulsion, nanoemulsion and self-emulsifying drug delivery systems. 
The present research work was aimed to develop SLNs of Ezetimibe to improve its oral bioavailability and give 
sustained release of drug. Glyceryl Monostearate (GMS) was selected as the solid lipid matrix for encapsulation of Ezetimibe in 
SLNs formulation prepared by High Speed homogenization technique. In this study the SLNs formulation was optimized by 
using 2-factor, 3- level 3
2 
full factorial design. After selecting the critical variables (independent variable) that is amount of 
lipid (GMS) and amount of surfactant (Poloxamer 188) affecting particle size and entrapment efficiency, the response surface 
methodology of the 3 
2 
full factorial designs are one of the most efficient designs to study the quadratic response surfaces and 
the second surfaces and the second order polynominal model. The optimized formulation was evaluated in terms of parameters 
like particle size, PDI, zeta potential, % EE, drug content and drug release. 
 
MATERIALS AND METHODS 
Ezetimibe was obtained as a gift sample from IPCA Laboratories, Mumbai, India. GMS and Poloxamer 188 (Pluronic F 
68) were purchased from Gattefosse, Mumbai, India and Balaji Drugs, Surat, India respectively. All the other reagents and 
solvents used were of analytical grade. Design Expert 10.0.2 software was used to optimize the formulation. 
 
Preliminary trials 
Preliminary trials were conducted to screen lipid and surfactant as well as to fix the stirring speed and stirring time. 
The effect on these factors on particle size and entrapment efficiency was used as criteria for screening. GMS and Poloxamer 
188 were selected and stirring time were fixed 500 rpm and 15 min respectively.
(13)
 
 
Preparation of Ezetimibe SLNs 
The design matrix was built by the statistical software package, design-expert (version 10.0.2) and Table 1 shows the 
factors and their respective levels. Table 2 indicates the quantitative formula of the batches. SLNs were prepared by using high 
speed homogenization technique. GMS was the melted lipid phase. Poloxamer 188 was dissolved in hot 80 ml of distilled 
water. The lipid phase maintained at a temperature of 70˚C, was added drop wise to the hot aqueous hot aqueous surfactant 
solution under stirring at 500 rpm for 15 min. with a mechanical stirrer. This resulted into formation of an emulsion which was the 
subsequently homogenized in a high speed homogenizer (IKA T25 
Digital S22 Homogenizer, India) for 15 minutes at 15000 rpm and maintained temperature at 80˚C. Later the mixture was 
cooled to room temperature yielding SLNs. 
 
Optimization of factorial design 
A 2-factor, 3-level design was used to statistically optimize the formulation parameters and evaluate main effects, 
interaction effects and quadratic effects of the formulation.  Two factors, amount of GMS (A) (X1) and amount of Poloxamer 
188 (B) (X 2) used were varied and their levels low medium and high medium were coded as -1, 0 and +1 respectively. The 
particle size (nm) (Y 1), %EE (Y2) and % cumulative drug release (Y 3 ) were taken as the response variables. In this design, 
experimental trials were performed at all 9 possible combinations. All other formulation variables and processing variables were 
kept invariant throughout the study. 
 
Y = b0+b1A+b2B+b12AB+b11 A2+b22B2                                                           Equation 2.1 
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Where Y is the measured response associated with each factor level combination; B 0 is an intercept; b1 and b2 are regression 
coefficients computed from the observed experimental values of Y. A and B are the coded levels of independent variables. The 
terms AB represent the interaction and A 
2 
and B
2
 represent quadratic terms. 
 
Differential Scanning Calorimetry (DSC) 
The thermogram of Ezetimibe, GMS and nanoparticles were obtained using Schimadzu DSC- 60 (Schimadzu Instruments, 
Japan) differential scanning calorimeter. 10 mg samples were placed in aluminium pans and heated from 25˚C to 300˚C at a 
scanning rate of 10˚C/min under nitrogen flow rate of 20 ml/min. An empty aluminium pan was used as reference. The instrument 
was calibrated with an Indium standard.(14) 
 
Drug Content 
1 ml SLNs dispersion was taken into 100 ml volumetric flask and volume was made up with methanol.  It was sonicated 
for 5 min in bath sonicator.  Solution was filtered through cellulose whatman filter paper (0.45µ) and filtrate was analysed at 
spectrophotometrically 233 nm. 
(15)
 
 
Particle size, Polydispersity index and Zeta potential 
Freeze dried nanoparticles  were dispersed in double distilled water. Particle size and Zeta potential was measured using a 
Malvern Zetasizer 3000 (Malvern Instruments, UK). 
The measurement of particle size was based on photon correlation spectroscopy. Polydispersity index was studied to determine the 
narrowness of the particle size distribution. Zeta potential was studied to determine the surface charge of SLNs. The zeta 
potential was determined using electrophoretic light scattering (ELS) at 25˚C with electric field strength of 23 V/cm using Zetasizer 
nano ZS. 
 
Percentage entrapment efficiency (%EE) 
Entrapment efficiency is defined as the ration of amount of entrapped drug to the amount of total drug used for preparation of 
nanoparticles. 2 ml of the SLNs dispersion was placed in centrifuge (Remi Instrument Ltd., Mumbai, India) at 10000 rpm for 30 min at 
4˚C. Supernatant was suitably diluted with methanol and analysed spectrophotometrically at 233 nm. 
 
EE (%)  * 100 
 
In vitro drug release study 
The dialysis membrane (Himedia, molecular cut off 12,000 to 14,000D) technique was used to characterize the prepared 
nanosuspension  using modified diffusion cell with 2.2 cm diameter and 55.95 cm2 surface area. The cell consisted of two 
chambers, the donor and the receptor. To one end of the open cylinder which acted as donor compartment, dialysis membrane-
150 was placed. SLNs were placed in the donor compartment. Receptor Compartment consisted of 50 ml of Acetate buffer pH 
4.5
(16) 
and was agitated continuously using magnetic stirrer. Temperature was maintained at 37±1°C throughout the study. 
Sample of 5 ml were withdrawn at predetermined time intervals (0.5,1, 2, 3, 4, 5, 12, 24 hours) and replaced by an equal 
volume of diffusion medium. Samples were analysed using UV-visible spectrophotometer at 232 nm. 
 
Counter plots and surface response plots 
Contour plots and surface response plots are diagrammatic representation of the values of the response.  They are helpful 
in explaining the relationship between independent and dependent variables. Response surface methodology (RSM) shows how an 
experimental response and a set of input variables are related. RSM sets a mathematical trend in the experimental design for 
determining the optimum level of experimental factors required for a given response. The reduced models were used to plot two 
dimension contour plots and three dimension RSM  at the values of A and B between -1 and +1 at predetermined value of particle 
size, %EE and % cumulative drug release. 
 
RESULTS AND DISCUSSION 
Formulation optimization of Ezetimibe loaded SLNs 
The present work was focused on the formulation development of Ezetimibe loaded Solid lipid nanoparticles for oral 
delivery. Based on the preliminary batches, GMS and Poloxamer 188 were selected as lipid and surfactant respectively whereas 
stirring time were fixed at 500 rpm and 30 min respectively. Preliminary studies decided the levels at which factors will be studied. 
Ezetimibe loaded nanoparticles were prepared nanoparticles were prepared by high speed homogenization technique. 
The effect of formulation variables namely amount of GMS (X1) and Poloxamer 188 (X2) was studied using 3
2 
factorial 
design. The particle size, %EE and %cumulative drug release (%CDR) for the 9 batches (B1 to B9) showed a variation and 
were found in range of 51.45 to 294.2 nm, 77.89% to 86.05% and 90.16 to 101.86%. The data clearly indicated the dependence 
of response variables on the selected independent variables. 
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Drug Content 
The drug content of all batches of SLNs is tabulated in Table 3. The drug content was found in the range of 98.21% to 
101.11% indicating that the Ezetimibe was uniformly distributed in nanoparticle dispersion and there was no loss of the material 
during the preparation.
(17)
 
 
Data analysis of Y 1 (Particle size) 
The particle size and PDI results of all the nine batches of Ezetimibe loaded SLNs are tabulated in Table 3. The particle 
sizes of batches B1-B9 were found in the range of 51.45 to 294.2 nm and the PDI was in the range of 0.044 to 0.506. That results 
indicated a profound effect of amount of GMS and Poloxamer 188 on the particle size.  The response (Y 1) obtained to various 
levels of two independent variables were subjected to multiple regression to give a quadratic polynomial equation. 
 
Y1=+158.41+56.38A-69.31B-31.34AB-25.41A2+10.81B2                                          Equation 2.2 
 
The above equation shows wide range of coefficient value. The model coefficients estimated by regression for particle size are 
shown in Table 4. The regression coefficients having P values 0.05 are highly significant. The terms A, B and AB were found to be 
significant. The terms A
2 
& B
2 
having P value 0.05 were insignificant in contributing to prediction of particle size. The reduced 
equation can now be written as 
 
Y1=+158.41+56.38A-69.31B-31.34AB                                            Equation 2.3 
 
The two independent variables A (amount of GMS) & B (amount of Poloxamer 188) as well as the interaction term (AB) 
were found to be significant (P   0.05) in affecting Y  1 (particle size). The positive co-efficient value for independent variable A 
(+56.38) indicated positive effect on dependent variable Y1.  As amount of lipid increases, the particle size increase. While 
negative coefficient for independent variable B (-69.31) which indicates as concentration of Surfactant increase particle siz 
decrease and interaction term AB (-31.34) indicated negative effect on dependent variable Y 1. The P value is 0.05 for all the 
response factors indicating that the models are significant. 
Batches B1 to B3 contained increasing amounts of GMS whereas amount of surfactant was constant (250 mg). The 
particle sizes of the batches B1, B2 & B3 were 113.7 nm, 256.9 nm and 294.2 nm respectively. An increase in particle size 
depends on the amount of lipid increased. This could probably be explained by the increase in aggregation of particles as the 
amount of GMS is increased. 
A similar trend of particle size was observed in batches B4 to B6 and batches B7 to B9. 
The particle sizes of the batches B1, B4 and B7 were 113.7, 86.41 and 51.45 nm respectively. 
A decrease in particle size was observed on increasing the amount of surfactant. A similar trend was observed in batches B2, B5, 
B8 and in B3, B6, and B7. 
The PDI is an important parameter that governs the physical stability of SLNs dispersion and should be as low as possible 
for the long term stability of SLNs dispersion. The PDI defined as dispersion homogeneity, has the range of 0 to 1. Values close to 
1 indicate heterogeneity and those less than 0.6 indicate homogeneity. The PDI value of all formulation was found in the range 
of 0.044 to 0.516 which was less than 0.6, indicating their homogeneity. Results indicated that all the formulation had a narrow 
particles size distribution. 
Zeta potential provides information related to the storage stability of colloidal dispersions. In general, the greater the 
zeta potential value of a nanoparticulate system, the better the colloidal suspension stability due to repulsion effect between 
charged nanoparticles. The zeta potential values ranged between -24 to -40 mV. The surfactant concentration affected the charge 
on the particle. As the concentration of surfactant increased there was decrease in the zeta potential value. This is because the 
surfactant is non- ionic and increasing its concentration lowers the total charge on the particle. 
Zeta potential values in the ± 15 mV to ± 50 mV are common for well stabilized nanoparticles. Hence, it was concluded that 
the nanoparticles would remain stable. 
(19)
 
 
Batches         Practicle        Zeta potential       Entrapment efficiency        (n=3) Drug                  (Mean+SD),  
                      size (nm)            (Mv) %                 (Mean+SD)                   content (%)                         (n=3) 
B1               113.7               0.044                       0.195                            84.30±0.381                98.21±1.402 
B2                256.9                    0.48                        -8.15                              85.24±0.323                99.78±1.642 
B3                294.2                   0.506                      -21.9                              86.05±0.455                100.13±1.486 
B4                86.41                    0.127                      -0.327                            80.09±0.510                100.58±0.877 
B5                149.1                    0.078                      -15.5                              81.67±0.434                98.51±0.969 
B6                188.9               0.433                      -11.2                              85.22±0.425                99.05±1.502 
B7                51.45                    0.264                      -0.941                            77.89±0.420                101.11±0.663 
B8                90.86                    0.184                 -0.213                            80.97±0.440                99.81±2.591 
B9               106.6                     0.112                      -1.6                                83.18±0.421                 98.96±1.805 
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Data analysis of Y 2 (%EE) 
% EE of SLNs was determined using ultracentrifugation method.  The % EE varied from 77.89±0.420 to 86.05±0.455. 
The results clearly indicated that Y2 is strongly affected by the amount of lipid and amount of surfactant selected for the study. 
The response Y 2 obtained at various levels of two independent variables were subjected to multiple regression to give a 
quadratic polynomial equation. 
 
Y2=+82.22+2.03A-2.26B+0.89AB+0.16A2+0.61B2                                 Equation 2.4 
 
The above equation shows wide range of coefficient values. The model coefficients estimated by multiple linear regression for 
%EE are shown in Table 4. The regression coefficients having P value 0.05 are highly significant. The terms AB, A 
2 
and B
2 
having P value 0.05 were insignificant in contributing to prediction of %EE. The reduced equation can now be written as 
 
Y2 =+82.22+2.03A-2.26B                                              Equation 2.5 
 
The two independent variables A (amount of GMS) & B (amount of Poloxamer 188) were found to be significant (P 
0.05) in affecting Y 2. The positive co efficient value for independent variable A (+2.03) indicated positive effect on dependent 
variable Y 2 .i.e. Amount of lipid increase will tend to increase %EE. The negative co efficient value for independent variable B 
(-2.26) indicated negative effect on dependent variable Y 2. Increase in surfactant concentration will tend to decrease the % 
Entrapment efficiency. Means as increase amount of surfactant, will tend to increase the solubility of drug in aqueous phase and 
drug is not available for encapsulate in lipid. In multiple regression analysis, the coefficient value of amount of lipid (A) of 
response Y 1 (Particle size) was +56.36 and the coefficient value of amount of lipid (A) of response Y2 (% EE) was +2.03 which 
indicate the effect of amount of lipid (A) on response Y1 (Particle size) was higher than compare to Y2 (%EE). Same as the 
coefficient value of amount of surfactant (B) of response Y 1 (Particle size) was -69.31 and the coefficient value of amount of 
surfactant (B) of response Y 2  (%EE) was -2.26 which indicate the effect of amount of surfactant (B) on response Y 1 
(Particle size) was higher than compare to Y 2 (%EE). 
Batches B1, B2 and B3 contained 500 mg, 850 mg and 1200 mg of GMS respectively whereas amount of surfactant was 
constant (250 mg). The %EE of the batches B1, B2 and B3 were 84.30%, 85.24% and 86.05% respectively. Increase in amount of 
lipid led to increase in %EE, which could be explained by more amount of the lipid available for Ezetimibe to dissolve. Similar trend 
was observed in batches B4 to B6 and B7 to B9. Our results were in agreement with findings of Yadav K et al.
(20)
 
 
Data analysis of Y 3 (% Cumulative drug release) 
In vitro drug release study of the Ezetimibe loaded SLNs was studied using modified dialysis method. The results 
(Figure 2) showed sustained release behaviour in acetate buffer pH 4.5. The response Y3 obtained at various levels of two 
independent variables were subjected to multiple regression to give a quadratic polynomial equation. 
 
Y3 =+93.99-3.31A+2.81B-0.57AB+0.17A2 +1.42B2                                             Equation 2.6 
 
The regression coefficients having P value 0.05 are highly significant. The terms AB, A 
2 
and B
2 
having P value 0.05 were 
insignificant in contributing to prediction of % CDR at 24 hour. The reduced equation can now be written as:  
 
Y3 =+93.99-3.31A+2.81B                                                    Equation 2.7 
 
The two independent variables A (amount of GMS) & B (amount of Poloxamer 188) were found to be significant (P 
0.05) in affecting Y 3. The negative co efficient value for independent variable A (-3.31) indicated negative effect on dependent 
variable Y 3.i.e. Amount of lipid increase will tend decrease in %CDR at 24 hour. The positive co efficient value for 
independent variable B (+2.81) indicated positive effect on dependent variable Y 3. Increase in amount of surfactant will 
tend to increase the % CDR at 24 hour.  Almost all batches showed the initial rapid drug release within two hours followed by 
85% drug release up to 24 h and beyond. The observed value for % CDR at 24 hours for all 9 batches B1-B9 varied from 
90.16 to 101.86%. The % CDR at 24 hour of the batches B1, B2 & B3 were 95.87%, 90.08% and 90.06% respectively. A 
decrease in % CDR at 24 h was observed on increasing the amount of lipid from 500 mg, 850 mg and 1200 mg. A similar 
trend of % CDR at 24 hour was observed in batches B4 to B6 and batches B7 to B9. The amount of lipid was in increasing order 
whereas the surfactant amount was constant at 500 mg and 750 mg respectively.
(21)
 
 
 
 
 
 
 
                                                   
www.iajpr.com 
P
ag
e6
6
6
 
Vol 7, Issue 08, 2017.                                                       Pranav Shah et al.                                                        ISSN NO: 2231-6876 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contour plots and response surface analysis 
Two-dimensional contour plots and 3-D response surface plots for variables Y 1 (particle size) are shown in Figure 3and 
Figure 4 respectively. Similarly, two dimensional contour plots and 3-D response surface plots for variables Y2 (%EE) are shown 
in Figure 5 and Figure 6 respectively. Two dimensional contour plots and 3-D response surface plots for variables Y 3 (%CDR at 
24 hour) 7 and 8 respectively.  In Figure 3 and Figure 4 the contour plot and 3-D response surface plot were developed for 
the particle size. Figure 3 and Figure 4 reveal a decline in particle size (51.45 nm) with an increase in amount of surfactant. 
Increase in amount of lipid led to an increase in particle size (294.2 nm). The lowest particle size was reported with the highest 
amount of surfactant and the lowest amount of lipid. 
In Figure 5 and Figure 6 the contour plot and 3-D response surface plot were developed for the % Entrapment 
efficiency. Figure 5 and Figure 6 reveal an increase in entrapment efficiency (86.05%) with an increase in amount of lipid. 
Increase in amount of surfactant led to decrease in %Entrapment efficiency (77.89%).The highest entrapment efficiency was 
obtained with the highest amount of lipid. 
In Figure 7 and Figure 8, the contour plot and 3-D response surface plot were developed for the % cumulative drug 
release at 24 hours (%CDR). %CDR increased from 90.16 to 101.86% with the increasing amount of surfactant (101.86%) 
and % CDR decreased to 90.16% with increase in amount of lipid. 
The optimum formulation was selected based on the criteria of attaining the constraints of variables response as 
shown in the Table 5. Upon ‘trading of' various response variables and comprehensive evaluation of feasibility search and exhaustive 
grid search, the formulation composition with amount of lipid 500mg and amount of Poloxamer 188 750mg were found to fulfil 
the maximum requisite of an optimum formulation because of minimum particle size, with good % Entrapment efficiency and 
Optimum % cumulative drug release at 24 hours. 
The zeta potential of optimized batch was found to be in the range (+30mv to -30mv) that indicate the formulation is 
stable. The zeta potential value of optimum formulation (batch B10) was −0.623 mV. This might be attributed to Poloxamer 188, 
a non-ionic surfactant which decreases the electrostatic repulsion between the particles and stearically stabilizes the nanoparticles 
by forming a coat around their surface. The negative charge of SLN may result from fatty acids released from the hydrolysis of 
GMS.(23) 
 
DSC Studies 
DSC thermogram of GMS showed the endothermic melting peak at 63.25
o 
C. DSC thermogram of physical mixture of 
drug and lipid (1:1) showed two distinct endothermic melting peaks for drug and lipid at 165.87°C and 58.48°C respectively. The 
intensity of melting peak of drug was reduced in physical mixture which may be due to dilution effect.  These results agreed with 
that of A.R.Gardouh et al. who studied the DSC analysis of GMS and found that melting endotherm of it was at 60.39°C. He 
also studied the DSC analysis of physical mixture of GMS and various model drug and found that the DSC thermogram of 
physical mixture showed the characteristic peaks of both GMS at 56°C with melting and degradation peaks of model drug. This 
indicates that there was no significant change in content of Ezetimibe in presence of GMS. 
DSC thermogram of GMS showed the endothermic melting peak at 63.25
o 
C. DSC thermogram of physical mixture of 
drug and lipid (1:1) showed two distinct endothermic melting peaks for drug and lipid at 165.87°C and 58.48°C respectively. 
The intensity of melting peak of drug was reduced in physical mixture which may be due to dilution effect.  These results agreed 
with that of A.R.Gardouh et al. who studied the DSC analysis of GMS and found that melting endotherm of it was at 60.39°C. 
He also studied the DSC analysis of physical mixture of GMS and various model drug and found that the DSC thermogram of 
physical mixture showed the characteristic peaks of both GMS at 56°C with melting and degradation peaks of model drug. This 
indicates that there was no significant change in content of Ezetimibe in presence of GMS. 
 
 
 
Figure 1. Diagram of solid lipid nanoparticle. 
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Figure 2. Drug release profile of batches B1-B9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Contour plot for Y 1 (Particle size). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Response surface plot for Y 1 (Particle size). 
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Figure 5. Contour plot for Y 2 (%EE). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Response surface plot for Y 2 (%EE). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Contour plot for Y 3 (%CDR). 
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Figure 8. Response surface plot for Y 3 (%CDR). 
 
 
 
Figure 9. Drug release profile of optimized batch (B10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Overlay plot. 
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Figure 11. DSC thermogram of GMS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. DSC thermogram of Physical mixture (Drug: Lipid) (1:1). 
 
Table 1. Execution of 32 full factorial designs. 
 
Batch B1 B2 B3 B4 B5 B6 B7 B8 B9 
Level of factor A -1 0 +1 -1 0 +1 -1 0 +1 
Level of factor B -1 -1 -1 0 0 0 +1 +1 +1 
 
Table 2. Formulation of SLNs Batches. 
 
Ingredients Batches 
B1 B2 B3 B4 B5 B6 B7 B8 B9 
Ezetimibe (mg) 10 
Glyceryl Monostearate (mg) 500 850 1200 500 850 1200 500 850 1200 
Poloxamer 188 (mg) 250 250 250 500 500 500 750 750 750 
distilled water (ml) 50 
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Table 3. Evaluation of batch B1-B9. 
 
Dependent 
variable 
Particle size (Y1) % EE (Y2) % CDR (Y3) 
P value Coefficient P value Coefficient P value Coefficient 
Intercept - +158.41 - +82.22 - +93.99 
A 0.0037 +56.36 0.0064 +2.03 0.0019 -3.31 
B 0.0020 -69.31 0.0047 -2.26 0.0030 +2.81 
AB 0.0331 -31.34 0.0931 +0.89 0.2406 -0.57 
A
2
 0.1205 -25.41 0.7739 +0.16 0.7712 +0.17 
B
2
 0.4273 +10.81 0.3199 +0.61 0.0817 +1.42 
 
Table 4. Summary of results of multiple regression analysis for response Y1, Y2 and Y3. 
 
Batches Particl
e size 
(nm) 
PDI Zeta 
potentia
l (mV) 
 % Entrapment 
efficiency 
(Mean±SD), (n=3) 
Drug content 
(%) (Mean±SD), 
(n=3) 
B1 113.7 0.044 -0.195 84.30±0.381 98.21±1.402 
B2 256.9 0.48 -8.15 85.24±0.323 99.78±1.642 
B3 294.2 0.506 -21.9 86.05±0.455 100.13±1.486 
B4 86.41 0.127 -0.327 80.09±0.510 100.58±0.877 
B5 149.1 0.078 -15.5 81.67±0.434 98.51±0.969 
B6 188.9 0.433 -11.2 85.22±0.425 99.05±1.502 
B7 51.45 0.264 -0.941 77.89±0.420 101.11±0.663 
B8 90.86 0.184 -0.213 80.97±0.440 99.81±2.591 
B9 106.6 0.112 -1.6 83.18±0.421 98.96±1.805 
 
Table 5. In vitro drug release profile of batch (n=3) (B1-B9). 
 
Time 
(min) 
B1 B2 B3 B4 B5 B6 B7 B8 B9 
0 0 0 0 0 0 0 0 0 0 
15 4.35 ± 
0.876 
4.29 ± 
0.506 
4.59 ± 
0.755 
4.94 ± 
0.695 
4.29 ± 
0.207 
4.92 ± 
0.326 
5.24 ± 
0.794 
4.94 ± 
0.358 
5.48 ± 
0.896 
30 7.85 ± 
1.699 
7.63 ± 
1.344 
7.34 ± 
0.979 
9.07 ± 
1.213 
9.21 ± 
0.860 
7.67 ± 
0.130 
9.55 ± 
0.848 
8.39 ± 
0.891 
8.71 ± 
0.359 
45 13.80 ± 
1.520 
12.46 ± 
1.312 
12.67 ± 
0.951 
13.29 ± 
1.067 
13.75 ± 
1.035 
11.66 ± 
0.876 
14.83 ± 
0.195 
13.01 ± 
0.632 
11.90 ± 
0.415 
60 21.02 ± 
2.530 
16.66 ± 
1.121 
17.01 ± 
1.355 
17.19 ± 
2.411 
17.98 ± 
1.925 
16.51 ± 
0.996 
18.22 ± 
0.314 
17.49 ± 
1.078 
15.67 ± 
1.042 
120 30.64 ± 
3.891 
24.50 ± 
0.800 
26.69 ± 
3.458 
25.80 ± 
2.199 
26.39 ± 
2.043 
24.61 ± 
1.350 
26.88 ± 
0.635 
26.79 ± 
1.538 
25.09 ± 
1.923 
180 40.81 ± 
4.922 
35.71 ± 
3.046 
35.32 ± 
3.908 
35.25 ± 
1.624 
35.79 ± 
2.471 
34.80 ± 
1.824 
37.32 ± 
2.086 
37.14 ± 
2.366 
34.81 ± 
2.652 
240 50.77 ± 
6.955 
45.23 ± 
3.947 
44.06 ± 
4.250 
45.71 ± 
1.694 
46.96 ± 
3.243 
46.06 ± 
1.401 
49.06 ± 
1.179 
47.5 ± 
2.975 
45.89 ± 
1.615 
300 60.98 ± 
8.141 
55.83 ± 
4.663 
55.12 ± 
3.975 
57.56 ± 
1.567 
59.15 ± 
5.752 
57.06 ± 
2.796 
62.46 ± 
0.492 
59.35 ± 
4.306 
56.36 ± 
2.415 
720 88.25 ± 
3.240 
79.01 ± 
1.649 
80.04 ± 
2.961 
83.26 ± 
1.079 
83.14 ± 
2.301 
81.03 ± 
1.792 
86.31 ± 
0.873 
84.03 ± 
2.059 
81.19 ± 
0.865 
1440 95.87 ± 
1.615 
90.08 ± 
1.513 
90.16 ± 
0.990 
97.17 ± 
0.315 
95.15 ± 
0.873 
91.27 ± 
1.031 
101.86 
± 1.135 
97.72 ± 
1.007 
94.25 ± 
0.959 
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Table 6. Formula for optimized batch (B10). 
 
Ingredients Quantity 
Ezetimibe 10 mg 
Glyceryl monostearate 500 mg 
Poloxamer 188 750 mg 
Distilled water 50 ml 
 
Table 7. Evaluation parameter for optimized batch (B10). 
 
Evaluation Parameters Results 
Particle size 38.91±2.23 nm 
% Entrapment efficiency 78.1±0.916 %(n=3) 
Drug content 100.78±1.200 % (n=3) 
PDI value 0.221±0.091 
Zeta potential -0.623 mV 
 
Table 8. In vitro diffusion study for optimized batch (B10). 
 
Time (min) % Cumulative drug release 
15 5.87±1.551 
30 10.89±1.768 
45 14.89±1.656 
60 20.03±0.891 
120 30.97±2.253 
180 39.23±2.944 
240 47.48±3.850 
300 57.46±5.258 
720 84.44±3.450 
1440 102.61±0.927 
 
Table 9. Results of optimized batch (B10 for response variables) 
 
Response Experimental Value Predicted Value 
Particle size (Y 1) 38.91 nm 48.49 nm 
%EE (Y 2 ) 78.1±0.916% 77.82% 
% CDR (Y 3) 102.61±0.927% 102.27% 
 
CONCLUSION 
The SLNs of Ezetimibe were successfully formulated using GMS as carrier lipid and Poloxamer 188 as a surfactant using 
High speed homogenization technique. The optimization of amount of lipid and amount of surfactant in the SLNs formulation was 
carried out using 3
2 
full factorial designs. The developed SLNs exhibited controlled drug release up to a period of 24 h. The 
developed formulation was found to be stable with no significant change in particle size, and drug content. The SLNs due to their 
size and lipophilic characteristics may be useful in avoiding the first pass metabolism. The Ezetimibe SLNs may provide a 
better bioavailability, reduction  in dose, dosing frequency, dose related side effects and better control of the disease. 
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